Gilde Healthcare bolsters its Private Equity team in Frankfurt office - Gilde Healthcare

Gilde Healthcare bolsters its Private Equity team in Frankfurt office

12 juli 2022
Utrecht (Nederland) en Frankfurt (Duitsland)

Dutch sector specialist Gilde Healthcare announces two new hires to its private equity team in Germany, following the recent close of its new €518m lower mid-market fund Gilde Healthcare Private Equity IV.

With the recruitment of Martin von Berg as Investment Manager and Lara Hilgert as Investment Analyst, the firm continues to expand its team in the region, following the arrival Robert Stein as Partner in 2021. Before joining Gilde Healthcare, Martin gained more than 5 years of private equity experience at 3i and Halder, where he was involved in healthcare services transactions. Martin started his career in the investment banking team of Bank of America in Frankfurt after graduating from the University of Mannheim with a MSc in Management. Lara joins Gilde Healthcare after finishing her MSc in Management at the London School of Economics. She successfully completed an internship at Gilde Healthcare last year and gained additional working experience at Roland Berger, Greenhill and PWC.

Gilde Healthcare completed four private equity transactions in Germany in the last 18 months and considers additional hires in the coming period.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €1.9 billion across two fund strategies: Private Equity and Venture&Growth. The firm is headquartered in Utrecht (The Netherlands) with local offices in Frankfurt (Germany) and Cambridge (United States). The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. The Private Equity fund targets healthcare providers, suppliers of medical products and service providers to pharma, medtech and healthcare. Gilde Healthcare’s Venture&Growth fund invests in therapeutics, medtech and healthtech in Europe and North America. Further information at www.gildehealthcare.com

Gilde Healthcare participates in $150M Series D financing of CatalYm

Proceeds will expand late-stage clinical development of lead programme visugromab’s into earlier lines of treatment including checkpoint naïve and second-line settings in randomized, controlled studies in select solid tumor indications Round brings on board new international...
16 juli 2024

Gilde Healthcare portfolio company Eetgemak joins forces with TotaalVERS to become the leading integrated healthcare foodservice provider

Combining TotaalVERS and Eetgemak will form a leading end-to-end foodservice provider*, offering a wide range of convenience meals, ingredients and groceries to the healthcare sector. The partnership emphasizes commitment to quality, service, and innovation in...
5 juli 2024

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone....
21 mei 2024